Key facts
- It has raised $17.7M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Boyu Capital, MSA Capital, ByteDance, Tianjin ByteDance Private Equity Fund Management, Boai Wanwu (Shanghai) Venture Capital Management — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Dynasty Gene
- ·The full record, as it builds
Funding rounds
No funding rounds for Dynasty Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dynasty Gene
Manufacturer of nucleic acid synthesis products designed for applications in molecular diagnostics, synthetic biology, and biomedical research. The company's platform utilizes a 3D inkjet printing ultra-high-throughput in situ DNA synthesis technology, enabling researchers and biotech companies to achieve high-precision, cost-effective, and scalable synthesis of DNA and RNA sequences for various applications.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 29
- Website
- dynastygene.com/
- Ownership
- Privately Held (backing)
Dynasty Gene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dynasty Gene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dynasty Gene in its N-PORT filings yet. We sweep new filings monthly.